Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2021 | 2022 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $311.0K | $0 |
| Cost of revenue | $0 | $0 | $364.0K | $0 |
| Gross profit | $0 | $0 | −$53.0K | $0 |
| Gross margin | — | — | -17.0% | — |
| R&D | $0 | $0 | $0 | $0 |
| Operating income | −$4 | −$2.6M | −$16.3M | $6.9M |
| EBITDA | $0 | −$2.6M | $215.0K | $593.0K |
| Net income | −$4 | $60.0K | $21.1M | −$17.1M |
| Net margin | — | — | 6777.5% | — |
| EPS (diluted) | -0.00 | 0.00 | 0.62 | -35.71 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds CLINU.
No tracked institution reports a position in CLINU as of their last filing.
No one on the platform has traded CLINU yet.
| -12.34% |
| $22M |
| — |
| ESLAEstrella Immunopharma, Inc. | $1.03 | +4.80% | $44M | — |
| GBRGGoldenbridge Acquisition Limited | $6.11 | -13.71% | $22M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.